Brief: Transcenta Says U.S. FDA Granted Orphan Drug Designation To Osemitamab (Tst001)
29/03/2023 10:53
March 29 (Reuters) - Transcenta Holding Limited
6628.HK :
* U.S. FDA GRANTED ORPHAN DRUG DESIGNATION TO OSEMITAMAB
(TST001)
Further company coverage: 6628.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcenta Holding
See all newsBrief: Transcenta Says Global Phase III Trial Of Osemitamab Approved By FDA, China, Korea Regulators
Brief: Transcenta Holding Says Unit To Sell CDMO Assets For RMB190.0 Million
Brief: Transcenta Holding To Revert Assets To Lilly For $4 Million Cash
Brief: Transcenta Therapeutics Appoints Dr. Christopher Hwang As Head Of Global Partnerships For Hicb Platform
Brief: Transcenta Announces Collaboration And Non-Exclusive Licensing Agreement With Eirgenix Inc.